Goodbye Gleevec? Sprycel, Tasigna Vie For Front-Line CML Leadership

BMS' Sprycel and Novartis' Tasigna perform better on key endpoints than standard of care, Gleevec, in first-line treatment of chronic myeloid leukemia.